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EDITORIAL
Bronchiolitis  and asthma:  the  next  step,
Bronquiolite  e  asma:  o  próximo  passo
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oAsthma  is  one  of  the  most  common  chronic  conditions  during
childhood.  The  origin  of  asthma  is  not  fully  understood,
but  it  is  clear  that  it  is  a  complex  disease  in  which  genetic
mechanisms  and  environmental  factors  are  involved.  In  this
issue  of  Jornal  de  Pediatria,  Brandão  et  al.  analyzed  the
relationship  between  acute  viral  bronchiolitis  during  the
ﬁrst  year  of  life  and  asthma  at  school  age  in  a  cohort  of
672  children  in  northeastern  Brazil.1 Acute  viral  bronchi-
olitis  was  deﬁned  according  to  the  American  Academy  of
Pediatrics  (AAP)  guidelines,  basically  requiring  a  combina-
tion  of  upper  and  lower  respiratory  symptoms  in  the  ﬁrst
year  of  life.  Even  after  adjusting  for  potential  confounders,
including  family  atopy  or  cigarette  smoke  exposure,  bron-
chiolitis  during  the  ﬁrst  year  of  life  was  independently
associated  with  asthma  at  school  age.  Why  is  this  study
important?  It  hints  to  the  possibility  that  we  may  be  able
to  prevent  asthma  by  preventing  viral  infection  during
early  childhood.  This  possibility  depends  on  the  causal
relationship  between  bronchiolitis  and  subsequent  asthma.
For  rhinovirus  bronchiolitis,  the  link  is  strong,  but  epidemi-
ological  studies  suggest  rhinovirus  bronchiolitis  ‘‘reveals’’
asthma  rather  than  causing  it.2,3 For  respiratory  syncytial
virus  (RSV),  the  link  is  less  strong,  but  the  association  might
well  be  causal.  RSV  infection  causes  a  robust  neutrophilic
airway  inﬂammation,  which  may  cause  persistent  changes
to  the  airways,4,5 resulting  in  chronic  airway  disease  without
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the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nausing  allergic  sensitization.  In  line  with  this  hypothesis,  a
revious  birth  cohort  study  by  Renato  Stein  demonstrated
hat  RSV  does  not  add  to  the  risk  of  allergic  sensitization.6
ausality  was  suggested  by  a  complex  longitudinal  study
y  Wu  et  al.  showing  that  the  time  gap  between  time  of
irth  and  the  peak  of  the  RSV  season  determines  the  risk
f  asthma  at  school  age.7 The  most  convincing  evidence
s  supposed  to  come  from  RSV  prevention  trials.  For  RSV
nfection,  most  trials  have  indicated  that  RSV  prevention
ecreases  the  risk  of  subsequent  wheeze,8--10 although  this
ould  not  be  conﬁrmed  in  a  recent  trial.11 The  results  of
hese  trials  should  be  considered  with  caution,  as  all  of
hem  where  performed  in  special  populations,  leaving  the
ossibility  that  the  direction  or  the  size  of  the  long-term
ffect  of  RSV  on  asthma  is  different  in  the  normal  pop-
lation.  Maternal  or  infant  vaccination  against  inﬂuenza
s  one  of  the  potential  interventions  to  be  considered.
ore  important,  probably,  are  the  currently  developed  RSV
accines.12 Several  companies  have  now  entered  the  clinical
evelopment  stage  of  their  RSV  vaccines.  A  nanoparticle-
ased  vaccine  for  maternal  vaccination  has  already  entered
hase  III.  This  vaccine  is  being  developed  with  the  support
f  the  Bill  and  Melinda  Gates  Foundation  and  is  intended
o  be  affordable,  therefore  it  would  be  available  in  high
s  well  as  low-  and  middle-income  countries.  The  clinical
SV  vaccine  programs  of  other  large  companies  follow
apidly,  so  it  appears  to  a  matter  of  time  before  we  have
n  RSV  vaccine.  These  upcoming  RSV  prevention  trials  in
he  normal  population  will  address  the  causal  link  between
SV  and  asthma,  and  show  the  potential  for  primary  asthma
revention.  The  clinical  development  of  all  RSV  vaccines
s  supported  by  studies  such  as  that  by  Brandão  et  al.,
hich  show  that  prevention  of  acute  viral  bronchiolitis  not
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nly  decreases  the  risk  of  a  life-threatening  acute  disease,
ut  may  also  impact  on  the  child’s  lung  health  throughout
hildhood  and  thereafter.
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